Genmab A/S (NASDAQ:GMAB) Short Interest Up 17.1% in March

Genmab A/S (NASDAQ:GMAB - Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,400,000 shares, a growth of 17.1% from the March 15th total of 2,050,000 shares. Currently, 0.4% of the company's shares are sold short. Based on an average trading volume of 626,600 shares, the days-to-cover ratio is currently 3.8 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Morgan Stanley reiterated an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and increased their target price for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, April 4th. Truist Financial reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $48.50.

Genmab A/S Stock Down 1.6 %

NASDAQ:GMAB traded down $0.48 during trading hours on Friday, reaching $29.26. 413,219 shares of the stock were exchanged, compared to its average volume of 390,206. The firm has a 50 day simple moving average of $29.27 and a 200-day simple moving average of $30.45. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.99. The stock has a market capitalization of $19.33 billion, a P/E ratio of 30.48, a P/E/G ratio of 2.10 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million for the quarter, compared to analysts' expectations of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. As a group, analysts expect that Genmab A/S will post 1.06 earnings per share for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Manhattan Co. acquired a new stake in shares of Genmab A/S during the 4th quarter worth approximately $26,000. Headlands Technologies LLC acquired a new stake in Genmab A/S in the 3rd quarter valued at approximately $27,000. Pinnacle Bancorp Inc. increased its position in Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock valued at $27,000 after acquiring an additional 638 shares during the period. NBC Securities Inc. acquired a new stake in Genmab A/S in the 3rd quarter valued at approximately $37,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Genmab A/S by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company's stock valued at $38,000 after acquiring an additional 498 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.